Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Genetic profiling of multiple myeloma in the novel agents era

Niccolò Bolli • 17 Sep 2020
SOHO Italy 2020
Multiple Myeloma Venetoclax

Niccolò Bolli, MD, PhD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, outlines the role of genetic profiling in multiple myeloma. Dr Bolli discusses the molecular heterogeneity of molecular myeloma and its importance in disease classification as well as precision medicine and highlights venetoclax, a BCL-2 inhibitor, which is effective in only a specific molecular subtype of multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Niccolò Bolli

2:26
The role of the bone marrow immune microenvironment on response to treatment in multiple myeloma
Niccolò Bolli • 25 Aug 2022
2:52
Genomically aggressive or indolent smoldering myeloma and progression to multiple myeloma
Niccolò Bolli • 25 Sep 2022
2:45
Clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progression
Niccolò Bolli • 25 Aug 2022
2:43
Session highlights: clonal hematopoiesis in multiple myeloma
Niccolò Bolli • 25 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals